trial

The Benefit of Minocycline on Negative Symptoms in Schizophrenia: Extent and Mechanisms

NCTId NCT02928965
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 207 (actual)
Sponsored by University of Manchester
Primary completion 2016-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
207 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2013-02
Primary completion
2016-05
Eligibility
ALL · 16 Years · 35 Years

Interventions & indications

Drugs
Minocycline

Sponsors

University of ManchesterLead Sponsor
University of EdinburghCollaborator
University of CambridgeCollaborator
University College, LondonCollaborator
University of BirminghamCollaborator
King's College LondonCollaborator
Manchester Mental Health & Social Care TrustCollaborator
Greater Manchester Mental Health NHS Foundation TrustCollaborator
Northern Care Alliance NHS Foundation TrustCollaborator
Lancashire Care NHS Foundation TrustCollaborator
Cambridgeshire and Peterborough NHS Foundation TrustCollaborator
West London Mental Health NHS TrustCollaborator
North East London Foundation TrustCollaborator
Central and North West London NHS Foundation TrustCollaborator
Camden and Islington NHS Foundation TrustCollaborator
South London and Maudsley NHS Foundation TrustCollaborator
NHS LothianCollaborator
NHS FifeCollaborator
NHS BordersCollaborator
University Hospital Birmingham NHS Foundation TrustCollaborator

Investigators

1
Bill Deakin, ProfessorPrincipal Investigator

Sites

0 total

Linked catalysts

1
The Benefit of Minocycline on Negative Symptoms in Schizophrenia: Extent and Mec — primary completion2016-05

Facts & assertions

4 sourced
Enrollment
207
Phase
PHASE2
Primary Completion Date
2016-05
Status
COMPLETED
relationships
The graph out of here
drug
Minocycline
drug
lead_sponsor
University of Manchester
company
collaborator
University of Edinburgh
company
University of Cambridge
company
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Psychotic Disorders
indication
Schizophrenia
indication
investigator
Bill Deakin, Professor
person